secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0000950170-25-036838
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus reports Q4 net loss $9.5M, cash $149.1M; pipeline updates on CRB-701, CRB-913, CRB-601
--------------------------------------------------------------------------------

- Net loss Q4 2024 $9.5M ($0.78/share) vs $8.0M ($1.81/share) in Q4 2023; full-year loss $40.2M ($3.68/share).
- Cash and investments $149.1M at Dec 31, 2024; expected to fund operations through Q3 2027.
- CRB-701 (Nectin-4 ADC) Phase 1 shows safety and responses in HNSCC, cervical, and mUC; FDA Fast Track for metastatic cervical cancer.
- CRB-913 obesity Ph1 SAD/MAD first dosing expected March 2025; CRB-601 first patient dosed Dec 2024, dose escalation Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000095017025036838/0000950170-25-036838-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000095017025036838/crbp-20250311.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-036838

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer